188 related articles for article (PubMed ID: 34680547)
1. A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer's Disease: Investigating Structure through Docking Studies.
Cho H; Hah JM
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680547
[TBL] [Abstract][Full Text] [Related]
2. Novel Tryptanthrin Derivatives with Selectivity as
Schepetkin IA; Karpenko OS; Kovrizhina AR; Kirpotina LN; Khlebnikov AI; Chekal SI; Radudik AV; Shybinska MO; Quinn MT
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375361
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease.
Shuai W; Bu F; Zhu Y; Wu Y; Xiao H; Pan X; Zhang J; Sun Q; Wang G; Ouyang L
J Med Chem; 2023 Jan; 66(2):1273-1300. PubMed ID: 36649216
[TBL] [Abstract][Full Text] [Related]
4. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.
Fricker M; Lograsso P; Ellis S; Wilkie N; Hunt P; Pollack SJ
Arch Biochem Biophys; 2005 Jun; 438(2):195-205. PubMed ID: 15907786
[TBL] [Abstract][Full Text] [Related]
5. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's disease.
Jun J; Yang S; Lee J; Moon H; Kim J; Jung H; Im D; Oh Y; Jang M; Cho H; Baek J; Kim H; Kang D; Bae H; Tak C; Hwang K; Kwon H; Kim H; Hah JM
Eur J Med Chem; 2023 Jan; 245(Pt 1):114894. PubMed ID: 36343411
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease.
Devi B; Jangid K; Kumar N; Kumar V; Kumar V
Mol Divers; 2024 Apr; ():. PubMed ID: 38573427
[TBL] [Abstract][Full Text] [Related]
8. c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases.
Hepp Rehfeldt SC; Majolo F; Goettert MI; Laufer S
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352989
[TBL] [Abstract][Full Text] [Related]
9. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
[TBL] [Abstract][Full Text] [Related]
10. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease.
Yarza R; Vela S; Solas M; Ramirez MJ
Front Pharmacol; 2015; 6():321. PubMed ID: 26793112
[TBL] [Abstract][Full Text] [Related]
11. MiR-335-5p Inhibits β-Amyloid (Aβ) Accumulation to Attenuate Cognitive Deficits Through Targeting c-jun-N-terminal Kinase 3 in Alzheimer's Disease.
Wang D; Fei Z; Luo S; Wang H
Curr Neurovasc Res; 2020; 17(1):93-101. PubMed ID: 32003672
[TBL] [Abstract][Full Text] [Related]
12. Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.
Zheng K; Park CM; Iqbal S; Hernandez P; Park H; LoGrasso PV; Feng Y
ACS Med Chem Lett; 2015 Apr; 6(4):413-8. PubMed ID: 25893042
[TBL] [Abstract][Full Text] [Related]
13. Identification and neuroprotective evaluation of a potential c-Jun N-terminal kinase 3 inhibitor through structure-based virtual screening and in-vitro assay.
Rajan RK; Ramanathan M
J Comput Aided Mol Des; 2020 Jun; 34(6):671-682. PubMed ID: 32040807
[TBL] [Abstract][Full Text] [Related]
14. Carbamate JNK3 Inhibitors Show Promise as Effective Treatments for Alzheimer's Disease: In Vivo Studies on Mouse Models.
Jun J; Moon H; Yang S; Lee J; Baek J; Kim H; Cho H; Hwang K; Ahn S; Kim Y; Kim G; Kim H; Kwon H; Hah JM
J Med Chem; 2023 May; 66(9):6372-6390. PubMed ID: 37094094
[TBL] [Abstract][Full Text] [Related]
15. The structure-based optimization of 3-substituted indolin-2-one derivatives as potent and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors and biological evaluation.
Li Z; Zhu G; Liu X; Gao T; Fang F; Dou X; Li Y; Zheng R; Jin H; Zhang L; Liu Z; Zhang L
Eur J Med Chem; 2023 Mar; 250():115167. PubMed ID: 36764123
[TBL] [Abstract][Full Text] [Related]
16. Targeting JNK3 for the treatment of neurodegenerative disorders.
Resnick L; Fennell M
Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking of C-Jun-N-Terminal Kinase (Jnk) with amino-pyrimidine derivatives.
Meenakumari K; Bupesh G
Bioinformation; 2020; 16(6):462-467. PubMed ID: 32884210
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis.
Xie X; Gu Y; Fox T; Coll JT; Fleming MA; Markland W; Caron PR; Wilson KP; Su MS
Structure; 1998 Aug; 6(8):983-91. PubMed ID: 9739089
[TBL] [Abstract][Full Text] [Related]
19. Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxic-ischaemic injury.
Pirianov G; Brywe KG; Mallard C; Edwards AD; Flavell RA; Hagberg H; Mehmet H
J Cereb Blood Flow Metab; 2007 May; 27(5):1022-32. PubMed ID: 17063149
[TBL] [Abstract][Full Text] [Related]
20. JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases.
Musi CA; Agrò G; Santarella F; Iervasi E; Borsello T
Cells; 2020 Sep; 9(10):. PubMed ID: 32998477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
